Last updated on April 21, 2014 at 8:40 EDT

Latest AnaptysBio Awarded U.S. Stories

2013-05-16 08:21:03

SHM-XEL platform to generate high thermostability antibodies for biodefense applications SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense applications. Under the terms of AnaptysBio's contract with the Science and Technology Corporation, AnaptysBio will be responsible for...